AbCellera Biologics Inc. Overview
AbCellera Biologics Inc., a pharmaceutical company based in Vancouver, Canada, operates within the health care sector. The company is renowned for its innovative approach to discovering and developing next-generation therapeutic antibodies. Utilizing a suite of advanced technologies, including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation, AbCellera aims to revolutionize the field of therapeutic antibodies.
Financial Snapshot
As of May 22, 2025, AbCellera Biologics Inc. closed at a price of $1.97 on the Nasdaq stock exchange. The company’s market capitalization stands at approximately $588 million USD. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $4.20 on May 30, 2024, and a 52-week low of $1.891 on April 6, 2025.
Mission and Operations
AbCellera’s mission is to serve customers in Canada by providing cutting-edge therapeutic solutions. The company’s focus on leveraging advanced technologies positions it at the forefront of the biopharmaceutical industry. By integrating various scientific disciplines, AbCellera aims to accelerate the discovery and development of therapeutic antibodies, addressing unmet medical needs.
For more detailed information about AbCellera Biologics Inc., including their latest developments and offerings, interested parties can visit their official website at www.abcellera.com .